Shortened High-dose Palliative Radiotherapy for Lung Cancer (SHiP-Rt)

University Hospitals Coventry and Warwickshire NHS Trust

Status

Enrolling

Conditions

Stage IV Lung Cancer

Treatments

Radiation: Radiotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT06483308

RS631323

Details and patient eligibility

About

The SHiP-Rt Study aims to investigate the safety and efficacy of reducing the number of RT fractions and RT duration, compared to the current standard of care (36Gy in 12 fractions over 16 days), by using shortened hypofractionated accelerated palliative radiotherapy (30Gy in 6 alternate-day fractions), aided by contemporary RT planning, verification, and delivery techniques.

Enrollment

37 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18
Patient has locally advanced (stage IIIB or IIIC) or metastatic (stage IV) NSCLC
Patient is treatment naïve or had limited progression after first-line systemic therapy (using chemotherapy, immunotherapy, or targeted therapy)
Patient is suitable for high dose palliative RT (36Gy in 12# or 39Gy in 13#)
Obtained written informed consent for the SHiP-Rt study.
Patients receiving RT after first-line systemic therapy must have a wash-out period of at least 3 weeks (i.e., 3-4 weeks).
Treatment naïve patients should be able to proceed to definitive systemic therapy without undue delay, i.e., within 3-4 weeks.

Exclusion criteria

Contraindication for thoracic RT
Requiring lung RT after second-line systemic therapy for NSCLC
Has more than 1 cancer that is requiring active treatment
On cytotoxic treatment for rheumatoid arthritis or connective tissue disorders
Poor life expectancy, likely less than 6 months
Patients with difficulty regarding compliance to the study treatment or follow-up
Previous radiotherapy to the same area